Clinical trials: Adolescents With Type 2 Diabetes
Type 2 Diabetes
TEEN HEED: An Adolescent Diabetes Prevention Intervention Incorporating Novel Mobile Health Technologies
The number of youth with type 2 diabetes in the U.S. is projected to increase by a staggering 49 percent by 2050, with higher rates among minority youth.
- Trial name
- NCT05560386
- Testing
- Text messaging, Virtual workshop
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Overweight and Obesity, PreDiabetes
Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation
The purpose of this research study is to determine whether continuous glucose monitors (CGM) are a safe, effective, and acceptable way to evaluate type 2 diabetes risk in youth as compared to the standard 2-hour oral glucose…
- Conditions
- Overweight and Obesity, PreDiabetes, Insulin Resistance
- Trial name
- NCT05404711
- Testing
- CGM
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mary Ellen Vajravelu, MD
Type2 Diabetes, Diabetes Mellitus
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both.
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D
- Trial name
- SURPASS-PEDS (NCT05260021)
- Testing
- Tirzepatide Dose 1, Tirzepatide Dose 2
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 99 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus.
- Trial name
- NCT02121483
- Testing
- empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 27 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Hypertension
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and…
- Conditions
- Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity
- Trial name
- NCT00001723
- Testing
- Orlistat
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Jack Yanovski
Pediatric Obesity
Family Focused Community Program to Prevent Type 2 Diabetes in Peripubertal Youth
Over one-third of children and adolescents are overweight and nearly 1 in 5 of them are obese. Metabolic syndrome, a strong predictor of Type 2 diabetes (T2D) and cardiovascular disease (CVD), occurs in up to 44% of obese youth…
- Trial name
- NCT02421198
- Testing
- YMCA Family Diabetes Prevention Program (YFDPP)
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Pediatric Obesity
Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity
As the prevalence of obesity rises in the U.S., so does the incidence of pediatric type 2 diabetes (T2D), which is associated with more aggressive disease progression than in adults.
- Trial name
- NCT04881799
- Testing
- Phentermine/Topiramate (Qsymia)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
The purpose of this study is to determine the pharmacokinetic and safety profile of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
- Trial name
- NCT00957268
- Testing
- Alogliptin
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Takeda
Cardiovascular Disease, Type 2 Diabetes
Complement and Cardiovascular Risk in Adolescents
This study evaluates how genetic variations in complement, a part of the immune system, affect cardiovascular risk in adolescents.
- Trial name
- CCRIA (NCT02821104)
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Type 2 Diabetes
Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
Background: The pill metformin treats diabetes. But it does not work for all youth, especially African-Americans. The injectable Liraglutide treats type 2 diabetes in adults.
- Trial name
- NCT02960659
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine (HOE901-U300) to Lantus in terms of change of HbA1c from baseline to endpoint (month 6) in children and adolescents with type 1 diabetes…
- Trial name
- EDITION JUNIOR (NCT02735044)
- Testing
- Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
- Where
- 107 sites in United States, Argentina and 22 more
- Volunteers
- 463 people
- Sponsor
- Sanofi
Diabetes Mellitus
Adjunctive Metformin Therapy in Double Diabetes
The significance of this project is to investigate the effects of adjunctive metformin therapy in children and adolescents with double diabetes.
- Trial name
- AMTIDD (NCT01334125)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Massachusetts, Worcester
Diabetes Mellitus, Type 1
A Study on the Effect of 2 Pen Devices on HbA1c
The purpose of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections achieves superior glycemic control, when compared to the conventional…
- Trial name
- NCT00985712
- Testing
- Insulin Lispro, Huminsulin Regular, HumaPen Memoir
- Where
- 29 sites in Germany
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2
Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)
The purpose of this study is to determine the key factors influencing insulin sensitivity in type 1 diabetes (T1DM) and maturity onset diabetes of the young, type 2 (MODY2).
- Conditions
- Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
- Trial name
- NCT02971202
- Testing
- Hyperinsulinemic, euglycemic clamp, 20% dextrose
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Type 2 Diabetes, Depression
Mindfulness-Based Intervention for Depression and Insulin Resistance in Adolescents
Rates of type 2 diabetes (T2D) in adolescents have escalated. Adolescent-onset is associated with greater health comorbidities and shorter life expectancy than adult-onset T2D.
- Conditions
- Type 2 Diabetes, Depression, Insulin Resistance, Obesity
- Trial name
- NCT04992299
- Testing
- Mindfulness-Based Intervention, Cognitive-Behavioral Therapy, Health Education
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Type 2 Diabetes
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)
This study will assess the safety, tolerability and pharmacokinetics of sitagliptin in 10 to 17 year old diabetic patients.
- Trial name
- NCT00730275
- Testing
- Sitagliptin phosphate
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes, Type 2 Diabetes
ACCESS: AI for pediatriC diabetiC Eye examS Study
The purpose of this study is to determine if providing in clinic point-of-care autonomous AI diabetic retinopathy exams improves screening rates compared to standard of care referral to an eye care provider, in a randomized…
- Trial name
- ACCESS (NCT05131451)
- Testing
- Point of Care Autonomous AI diabetic retinopathy exam
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type II
Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has sponsored a consortium of investigators to conduct a clinical treatment trial, Treatment Options for type…
- Trial name
- TODAY (NCT00081328)
- Testing
- Metformin, Rosiglitazone, Lifestyle Program
- Where
- 16 sites in United States
- Volunteers
- 699 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 2
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
The purpose of this research study is to evaluate the efficacy and safety of an empagliflozin dosing regimen and one dose of linagliptin in patients with type 2 diabetes who are aged 10 to below 18 years and are currently taking…
- Trial name
- NCT03429543
- Testing
- Metformin, Insulin, Linagliptin
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 175 people
- Sponsor
- Boehringer Ingelheim